As reported in PBR, MedImmune has signed a licensing deal with Amgen for its AMG-108 monoclonal to the IL-1 pathway. MedImmune has secured worldwide rights outside of Japan. Amgen received an undisclosed upfront payment with additiona milestones and royalties on commercial sales.
MedImmune believes the IL-1 pathway is important in a variety of inflammatory conditions, and AMG 108 represents a compelling opportunity for it to explore this antibody's activity against various diseases for which patients need new treatment options.
Posted by Bruce Lehr Jan 14th 2011.
Comments